Skip to main content
. 2013 Feb 1;5(1):3. doi: 10.1186/1868-7083-5-3

Figure 2.

Figure 2

Pharmacokinetics of 5-AZA-CdR at a dose of 15 mg/m2 as a three-hour i.v. infusion to patients with AML and MDS [[92]]. After i.v. infusion of 5-AZA-CdR, it reaches a steady-state plasma level within two hours, confirming its very short half-life. 5-AZA-CdR, 5-aza-2′-deoxycytidine; AML, acute myeloid leukemia; i.v., intravenous; MDS, myelodysplastic syndrome.